Treatment of bipolar disorder during pregnancy

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 9, 2007, Pages 4-9

  Cohen, Lee S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Simches Research Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM CARBONATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OXCARBAZEPINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AWARENESS; BIPOLAR DISORDER; CARDIOVASCULAR MALFORMATION; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONGENITAL HEART MALFORMATION; CRANIOFACIAL MALFORMATION; DISEASE SEVERITY; DRUG SAFETY; FETUS ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; MORBIDITY; NERVOUSNESS; NEURAL TUBE DEFECT; PRACTICE GUIDELINE; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPINA BIFIDA; TACHYPNEA; TERATOGENICITY; TREMOR; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; FEMALE; PREGNANCY COMPLICATION; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE;

EID: 35348996675     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 1998;59(suppl 2):18-28
2. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychosis. Br J Psychiatry 1987;150:662-673
3. Grof P, Robbins W, Alda M, et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000;61:31-39
4. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-184
5. Viguera AC. Women and bipolar disorder: morbidity risk during pregnancy and the postpartum. Presented at the 5th meeting of the International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pa
6. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507
7. Viguera AC, Cohen LS, Bouffard S, et al. Reproductive decisions by women with bipolar disorder after prepregnancy psychiatric consultation. Am J Psychiatry 2002;159:2102-2104
8. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150
9. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-320
10. Marangell LB, Suppes T, Ketter TA, et al. Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids 2006;75:315-321
11. Meadows M. Pregnancy and the drug dilemma. FDA Consumer Magazine 2001 (May-June). Available at: http://www.fda/gov/fdac/features/2001/301_preg.html. Accessed Feb 27, 2007
12. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606
13. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000;20:399-403
14. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-449
15. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722
16. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006;163:313-315
17. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004;161:163-165
18. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-827
19. Hallberg P, Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005;25:59-73
20. GlaxoSmithKline. New Safety Information Regarding Paroxetine: Findings Suggest Increased Risk Over Other Antidepressants, of Congenital Malformations, Following First Trimester Exposure to Paroxetine. 2005. Available at http://www.gsk.ca/en/health_info/PAXIL_PregnancyDHCPL_E-V4.pdf. Accessed Jun 15, 2006
21. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-308
22. GlaxoSmithKline. New Safety Information Regarding Paroxetine: Second Large Study Shows an Increased Risk of Cardiac Defects, Over Other Antidepressants, Following First Trimester Exposure to Paroxetine. 2005. Available at http://www.womensmentalhealth.org/resources/PDFs/ GSK_Canada_Paxil_Letter.pdf. Accessed Jun 15, 2006
23. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675-2683
24. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-2692
25. Greene MF. Teratogenicity of SSRIs - serious concern or much ado about little? [editorial]. N Engl J Med 2007;356:2732-2733
26. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-508
27. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-610
28. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003;17:255-261
29. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015
30. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368-375
31. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002;159:2055-2061
32. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-1895
33. Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004;7:193-200
34. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-2248
35. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-176
36. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-587
37. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-1099
38. Weinstein MR. The International Register of Lithium Babies. Drug Information J 1976;10:94-100
39. Nora JJ, Nora AH, Toews WH, et al. Lithium, Ebstein's anomaly and other congenital heart defects. Lancet 1974;1:594-595
40. McElroy SL. Bipolar disorder: special diagnostic and treatment considerations in women. CNS Spectr 2004;9(8 suppl 7):5-18
41. Kruger S, Trevor Young L, Braunig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord 2005;7:205-215
42. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965
43. Omtzigt J, Los F, Grobbee D, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-125
44. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98:168-175
45. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21
46. Cunnington M, Tennis P, for the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-960
47. Tennis P, Eldridge RR, for the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002;43:1161-1167
48. GlaxoSmithKline. Health Canada endorsed important safety information on Lamictal (lamotrigine) tablets. Aug 1, 2006. Available at: http://www.gsk.ca/en/ health_info/LAMICTAL_DHCPL_ENG_FNL.pdf. Accessed Jul 10, 2007
49. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals: lamotrigine (marketed as Lamictal). Sept 28, 2006. Available at: http://www.fda.gov/cder/drug/InfoSheets/ HCP/lamotrigineHCP.htm. Accessed Jul 10, 2007
50. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677
51. Viguera AC, Cohen LS, Baldessarini RJ, et al. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002;47:426-436
52. Jones KL, Lacro R, Johnson K, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-1666
53. Wisner KL, Peindl KS, Perel JM, et al. Verapamil treatment for women with bipolar disorder. Biol Psychiatry 2002;51:745-752
54. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997;22:192-196
55. Brockington IF, Cernik KF, Schofield EM, et al. Puerperal psychosis. Arch Gen Psychiatry 1981;38:829-833
56. Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995;152:1641-1645